Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Liabilities and Shareholders Equity (2016 - 2025)

Heron Therapeutics' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $255.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 9.75% year-over-year to $255.9 million; the TTM value through Dec 2025 reached $972.7 million, up 9.3%, while the annual FY2025 figure was $255.9 million, 9.75% up from the prior year.
  • Liabilities and Shareholders Equity reached $255.9 million in Q4 2025 per HRTX's latest filing, up from $249.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $404.2 million in Q2 2021 to a low of $201.2 million in Q2 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $257.5 million, with a median of $239.9 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 39.65% in 2022, then increased 12.76% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $305.7 million in 2021, then dropped by 17.91% to $251.0 million in 2022, then decreased by 11.33% to $222.5 million in 2023, then grew by 4.78% to $233.1 million in 2024, then grew by 9.75% to $255.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Liabilities and Shareholders Equity are $255.9 million (Q4 2025), $249.0 million (Q3 2025), and $232.1 million (Q2 2025).